Pricing Log in Create free account

Alto Neuroscience, Inc. (ANRO) vs Cullinan Therapeutics, Inc. (CGEM)

Alto Neuroscience, Inc. and Cullinan Therapeutics, Inc. are both Biotechnology companies. Alto Neuroscience, Inc. and Cullinan Therapeutics, Inc. are of similar size ($901.0M and $887.7M). Across the 9 metrics below, Alto Neuroscience, Inc. leads on 6 and Cullinan Therapeutics, Inc. on 3.

Valuation

Metric ANRO CGEM Biotechnology median
P/E n/m n/m 8.50
P/S n/m n/m 9.71
P/B 4.31 2.47 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m n/m 9.21
Earnings yield (10.97%) (23.98%) (33.15%)
Free cash flow yield (7.29%) (20.03%) (25.50%)

Profitability

Metric ANRO CGEM Biotechnology median
Gross margin — — 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (49.17%) (50.30%) (56.36%)
Return on assets (40.90%) (46.30%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ANRO CGEM Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 12.40% (20.86%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric ANRO CGEM Biotechnology median
Debt to equity 0.09 0.00 0.00
Current ratio 14.85 8.42 4.72
Net debt to EBITDA 2.40 1.57 0.96

Dividend

Metric ANRO CGEM Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ANRO CGEM Biotechnology median
Market cap 887.66m 900.97m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack